@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix this: <http://bio2rdf.org/drugbank_resource:DB00196_DB08895_nanopub.RAVVjAOg20XdvFiJYPVjro6K60yeFaBteTQKesWmDumgQ> .
@prefix sub: <http://bio2rdf.org/drugbank_resource:DB00196_DB08895_nanopub.RAVVjAOg20XdvFiJYPVjro6K60yeFaBteTQKesWmDumgQ#> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix pav: <http://purl.org/pav/> .
@prefix orcid: <http://orcid.org/> .
@prefix codebase: <https://github.com/tkuhn/bio2rdf2nanopub> .
@prefix version: <https://github.com/tkuhn/bio2rdf2nanopub/tree/eda7951a5f6c622c5d2132f50c3093138484a349> .
@prefix instance: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB> .
@prefix process: <https://github.com/tkuhn/bio2rdf2nanopub#instance.MIIBtzCCASwGByqGSM44BAEwggEfAoGB.3c184e6c-ceb8-4275-a679-71dfbdac2a11> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix has-source: <http://semanticscience.org/resource/SIO_000253> .
@prefix d: <http://bio2rdf.org/drugbank:> .
@prefix dv: <http://bio2rdf.org/drugbank_vocabulary:> .
@prefix dr: <http://bio2rdf.org/drugbank_resource:> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:publicationInfo;
    a np:Nanopublication .
}

sub:assertion {
  d:DB00196 dv:ddi-interactor-in dr:DB00196_DB08895 .
  
  d:DB08895 dv:ddi-interactor-in dr:DB00196_DB08895 .
  
  dr:DB00196_DB08895 dcterms:identifier "drugbank_resource:DB00196_DB08895";
    dcterms:title "DDI between Fluconazole and Tofacitinib - Fluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily."@en;
    a dv:Drug-Drug-Interaction;
    rdfs:label "DDI between Fluconazole and Tofacitinib - Fluconazole (and other strong CYP2C19 inhibitors and moderate CYP3A4 inhibitors), when used in combination with tofacitinib, may increase tofacitinib concentration. It is recommended to modify therapy by reducing the adult dose of tofacitinib from 5mg twice a day to 5mg daily.  [drugbank_resource:DB00196_DB08895]"@en .
}

sub:provenance {
  sub:assertion has-source: dr:bio2rdf.dataset.drugbank.R3 .
}

sub:publicationInfo {
  sub:signature.MC4CFQCNrthghkIR npx:hasPublicKey "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";
    npx:hasSignature "MC4CFQCNrthghkIR319UqEdnSA3qqI0oHAIVAIKFEGBmiBMdLP8BL0njBAygBqUU";
    npx:signedBy instance: .
  
  this: dcterms:created "2018-03-30T11:12:42.983+02:00"^^xsd:dateTime;
    dcterms:license <https://creativecommons.org/licenses/by-nc/4.0/>;
    npx:hasSignatureElement sub:signature.MC4CFQCNrthghkIR;
    prov:wasGeneratedBy process: .
  
  instance: prov:specializationOf codebase:;
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
  
  process: dcterms:identifier "3c184e6c-ceb8-4275-a679-71dfbdac2a11";
    prov:used version:;
    prov:wasAssociatedWith instance:;
    prov:wasStartedBy orcid:0000-0002-1267-0234 .
  
  version: dcterms:isVersionOf codebase:;
    pav:version "eda7951a5f6c622c5d2132f50c3093138484a349";
    prov:wasAttributedTo orcid:0000-0002-1267-0234 .
}